Optimove Launches Engage to End 'Content Chaos' in the GenAI Age
Built into Optimove's Positionless Marketing Platform, Engage is the engine behind Creative Power enabling real-time content creation, management, and optimization
New York, May 11, 2025 (GLOBE NEWSWIRE) -- Optimove, the leader in Positionless Marketing, today announced the launch of Optimove Engage, an AI-powered solution that empowers marketers to scale the creation, management, and optimization of personalized content across every channel.In the GenAI era, generating personalized content is easier than ever. But with infinite permutations now possible, a new challenge has emerged: how to manage, test, and optimize it without spiraling into content chaos that's overwhelming many marketing teams today.
Optimove Engage provides marketing teams with:
GenAI-powered, brand-compliant content creation and management across all channels
AI-led message analysis that identifies each customer's content palette and continuously optimizes delivery
A marketer-friendly UI to facilitate true messaging symmetry across outbound and inbound channels
'GenAI has empowered anyone to create content instantly. While that's accelerated creativity, it's also unleashed a runaway train of content chaos,' said Shai Frank, SVP Product & GM Americas at Optimove. 'Engage is the engine behind Creative Power in our Positionless Marketing platform, enabling real-time content creation, management, and optimization at scale. It's built for marketers to meet today's customer expectations, where speed and relevance are everything. With Engage, marketers can truly be positionless, executing AI-assisted campaigns with control that drives engagement and loyalty.'
Optimove Engage adds a powerful content optimization layer to the Optimove Positionless Marketing Platform. It joins:
Optimove Orchestrate – the industry standard-setting orchestration and decisioning engine, providing a Single Marketing View of all campaigns across channels and vendors
Opti-X – the personalization engine that delivers tailored digital experiences at scale
Adact.me – the AI-orchestrated gamification solution enhancing engagement and retention
– the foundational, generative, and agentic AI framework behind Optimove
Together, these solutions empower marketers to deliver real-time, individualized journeys with full visibility and control. All within a single, unified platform. The Positionless Marketing Platform Powers the Entire Marketing Workflow
Optimove's Positionless Marketing Platform is built on three foundational powers:
Data Power – Allowing marketers to discover customer insights instantly for precise targeting and hyper-personalization.
Creative Power – Empowering marketers to generate channel-ready assets like copy and visuals instantly.
Optimization Power – Enabling complete marketing teams to run self-optimizing campaigns through automated journeys and testing.
With Optimove's Positionless Marketing Platform, marketers gain full control over the entire marketing lifecycle, executing any task instantly and independently. From orchestration to optimization, it lets marketers break free from the limitations of fixed roles and gain the power to execute any marketing task instantly and independently to do anything and be everything.
About Optimove Optimove, the leader in Positionless Marketing, frees marketing teams from the limitations of fixed roles, giving every marketer the power to execute any marketing task instantly and independently. Positionless Marketing has been proven to improve campaign efficiency by 88%, allowing marketing teams to create more personalized engagement with existing customers. Optimove is recognized as the Visionary Leader in Gartner's Magic Quadrant for Multichannel Marketing Hubs. Being a visionary leader is a hallmark of Optimove. It was the first CRM Marketing Platform to natively embed AI with the ability to predict customer migrations between lifecycle stages in 2012. Today, its comprehensive AI-powered suite is at the leading edge of empowering marketers to optimize workflows from Insight to Creation and through Orchestration. Optimove provides industry-specific and use-case solutions for leading consumer brands globally. For more information, go to Optimove.com
CONTACT: Rob Wyse Optimove +2129201470 Rob_W@optimove.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
36 minutes ago
- Associated Press
KAYTUS Unveils Upgraded MotusAI to Accelerate LLM Deployment
SINGAPORE--(BUSINESS WIRE)--Jun 12, 2025-- KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, today announced the release of the latest version of its MotusAI AI DevOps Platform at ISC High Performance 2025. The upgraded MotusAI platform delivers significant enhancements in large model inference performance and offers broad compatibility with multiple open-source tools covering the full lifecycle of large models. Engineered for unified and dynamic resource scheduling, it dramatically improves resource utilization and operational efficiency in large-scale AI model development and deployment. This latest release of MotusAI is set to further accelerate AI adoption and fuel business innovation across key sectors such as education, finance, energy, automotive, and manufacturing. This press release features multimedia. View the full release here: MotusAI Dashboard As large AI models become increasingly embedded in real-world applications, enterprises are deploying them at scale, to generate tangible value across a wide range of sectors. Yet, many organizations continue to face critical challenges in AI adoption, including prolonged deployment cycles, stringent stability requirements, fragmented open-source tool management, and low compute resource utilization. To address these pain points, KAYTUS has introduced the latest version of its MotusAI AI DevOps Platform, purpose-built to streamline AI deployment, enhance system stability, and optimize AI infrastructure efficiency for large-scale model operations. Enhanced Inference Performance to Ensure Service Quality Deploying AI inference services is a complex undertaking that involves service deployment, management, and continuous health monitoring. These tasks require stringent standards in model and service governance, performance tuning via acceleration frameworks, and long-term service stability, all of which typically demand substantial investments in manpower, time, and technical expertise. The upgraded MotusAI delivers robust large-model deployment capabilities that bring visibility and performance into perfect alignment. By integrating optimized frameworks such as SGLang and vLLM, MotusAI ensures high-performance, distributed inference services that enterprises can deploy quickly and with confidence. Designed to support large-parameter models, MotusAI leverages intelligent resource and network affinity scheduling to accelerate time-to-launch while maximizing hardware utilization. Its built-in monitoring capabilities span the full stack—from hardware and platforms to pods and services—offering automated fault diagnosis and rapid service recovery. MotusAI also supports dynamic scaling of inference workloads based on real-time usage and resource monitoring, delivering enhanced service stability. Comprehensive Tool Support to Accelerate AI Adoption As AI model technologies evolve rapidly, the supporting ecosystem of development tools continues to grow in complexity. Developers require a streamlined, universal platform to efficiently select, deploy, and operate these tools. The upgraded MotusAI provides extensive support for a wide range of leading open-source tools, enabling enterprise users to configure and manage their model development environments on demand. With built-in tools such as LabelStudio, MotusAI accelerates data annotation and synchronization across diverse categories, improving data processing efficiency and expediting model development cycles. MotusAI also offers an integrated toolchain for the entire AI model lifecycle. This includes LabelStudio and OpenRefine for data annotation and governance, LLaMA-Factory for fine-tuning large models, Dify and Confluence for large model application development, and Stable Diffusion for text-to-image generation. Together, these tools empower users to adopt large models quickly and boost development productivity at scale. Hybrid Training-Inference Scheduling on the Same Node to Maximize Resource Efficiency Efficient utilization of computing resources remains a critical priority for AI startups and small to mid-sized enterprises in the early stages of AI adoption. Traditional AI clusters typically allocate compute nodes separately for training and inference tasks, limiting the flexibility and efficiency of resource scheduling across the two types of workloads. The upgraded MotusAI overcomes traditional limitations by enabling hybrid scheduling of training and inference workloads on a single node, allowing for seamless integration and dynamic orchestration of diverse task types. Equipped with advanced GPU scheduling capabilities, MotusAI supports on-demand resource allocation, empowering users to efficiently manage GPU resources based on workload requirements. MotusAI also features multi-dimensional GPU scheduling, including fine-grained partitioning and support for Multi-Instance GPU (MIG), addressing a wide range of use cases across model development, debugging, and inference. MotusAI's enhanced scheduler significantly outperforms community-based versions, delivering a 5× improvement in task throughput and 5× reduction in latency for large-scale POD deployments. It enables rapid startup and environment readiness for hundreds of PODs while supporting dynamic workload scaling and tidal scheduling for both training and inference. These capabilities empower seamless task orchestration across a wide range of real-world AI scenarios. About KAYTUS KAYTUS is a leading provider of end-to-end AI and liquid cooling solutions, delivering a diverse range of innovative, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at and follow us on LinkedIn and X. View source version on CONTACT: Media Contacts [email protected] KEYWORD: EUROPE SINGAPORE SOUTHEAST ASIA ASIA PACIFIC INDUSTRY KEYWORD: APPS/APPLICATIONS TECHNOLOGY OTHER TECHNOLOGY SOFTWARE NETWORKS INTERNET HARDWARE DATA MANAGEMENT ARTIFICIAL INTELLIGENCE SOURCE: KAYTUS Copyright Business Wire 2025. PUB: 06/12/2025 07:11 AM/DISC: 06/12/2025 07:10 AM
Yahoo
36 minutes ago
- Yahoo
Gene Therapy Collaboration and Licensing Deals Report and Directory 2025: Explore the Financials Behind 787 Gene Therapy Licensing Deals from 2016-2025
The Gene Therapy Collaboration and Licencing Deals report features 787 deals with financial terms and SEC contracts. Explore trends in R&D partnerships, commercialization strategies, and IP structures. Ideal for benchmarking deal terms, assessing opportunities, and streamlining due diligence in the gene therapy space. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy Collaboration and Licensing Deals 2016-2025" report has been added to report contains a comprehensive listing of 787 gene therapy deals announced since 2016, including financial terms where available, and links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the world's leading biopharma revised and updated, the report provides details of gene therapy deals from 2016 to report provides a detailed understanding and analysis of how and why companies enter gene therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of report includes collaboration, development, research and licensing initial chapters of this report provide an orientation of gene therapy dealmaking. Chapter 1 introduces the report, while Chapter 2 provides an overview of the trends in gene therapy dealmaking since 2016. Chapter 3 offers a summary of the leading gene therapy deals since 2016, listed by headline value. Chapter 4 lists the top 25 most active companies in gene therapy dealmaking, with summaries and comprehensive listings of deals. Chapter 5 and Chapter 6 offer detailed reviews of gene therapy deals and partnering deals announced since Jan 2016, focusing on contract documents in the public domain and specific gene therapy technologies report also includes numerous tables and figures that illustrate the trends and activities in gene therapy deal making since 2016. In addition, a comprehensive deal directory is provided, organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on Therapy Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse gene therapy collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Report ScopeGene Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene therapy trends and structure of deals entered into by leading biopharma companies Therapy Collaboration and Licensing Deals includes: Trends in gene therapy dealmaking in the biopharma industry Directory of gene therapy deal records covering pharmaceutical and biotechnology The leading gene therapy deals by value Most active gene therapy licensing dealmakers Gene Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered:Chapter 1 - IntroductionChapter 2 - Trends in gene therapy dealmaking2.1. Introduction2.2. Gene therapy deals over the years2.3. Most active gene therapy dealmakers2.4. Gene therapy deals by deal type2.5. Gene therapy deals by therapy area2.6. Gene therapy deals by industry sector2.7. Deal terms for gene therapy deals2.7.1 Gene therapy deals headline values2.7.2 Gene therapy deal upfront payments2.7.3 Gene therapy deal milestone payments2.7.4 Gene therapy royalty ratesChapter 3 - Leading gene therapy deals3.1. Introduction3.2. Top gene therapy deals by valueChapter 4 - Most active gene therapy dealmakers4.1. Introduction4.2. Most active gene therapy dealmakers4.3. Most active gene therapy deals company profilesChapter 5 - Gene therapy contracts dealmaking directory5.1. Introduction5.2. Gene therapy contracts dealmaking directoryChapter 6 - Gene therapy dealmaking by technology typeDeal directory Deal directory - Gene therapy deals by company A-Z Deal directory - Gene therapy deals by deal type Deal directory - Gene therapy deals by therapy area For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
36 minutes ago
- Yahoo
Monaco: at the Yacht Club, Blumorpho pushes maritime finance forward, 'No time to waste'
MONACO, June 12, 2025 (GLOBE NEWSWIRE) -- The ecological transition of the maritime and port sectors has reached a critical inflection point. In a high-level working session held at the Yacht Club de Monaco, innovation met finance to chart a clear course toward healthier oceans and sustainable infrastructure. The event, led by Blumorpho in partnership with the International Association of Port Cities (AIVP) and supported by the Prince Albert II of Monaco Foundation, brought together port authorities, financial institutions, corporations, and innovators to activate actionable financial mechanisms for the sustainable transformation of coastal urban ecosystems. Part of the momentum building toward the 'Blue Economy Finance Forum' and the UN Ocean Conference (UNOC), the initiative aims to accelerate the deployment of scalable, investable solutions in support of net-zero and biodiversity objectives. Opening the session, Bernard d'Alessandri, General Secretary of the Yacht Club de Monaco, stated: 'On behalf of our President, HSH Prince Albert II, we are pleased to welcome you to the Yacht Club de Monaco to address this key issue. We would like to congratulate the Blumorpho team for their initiative and leadership. On our side, and as part of our collective ambition, 'Monaco, Capital of Advanced Yachting', we are fully committed to advancing sustainable yachting through concrete actions, including the development of the SEA Index®, a tool to assess the carbon footprint of superyachts; and support for pioneering projects through the Monaco Energy Boat Challenge (1–5 July 2025). This commitment is more essential than ever, and we are proud to contribute to the dialogue on how to protect our Ocean.' The day unfolded through expert panels, collaborative workshops, and project showcases, with three core themes emerging: ports as platforms for systemic innovation, strategic capital for climate impact, and concrete, investment-ready projects. Port cities were highlighted as drivers of integrated innovation, connecting clean energy, biodiversity, mobility, and industrial transformation. Financially, new models are gaining traction, from blended finance and blue bonds to private equity and infrastructure debt. Flagship projects from Kribi, Riga, San Diego, Genoa, and Bordeaux showcased pathways that combine decarbonization, aquaculture, digital infrastructure, and inclusive growth. 'The real challenge is not only funding the transition, but designing collaborative and business models that align profitability with long-term climate and societal goals,' explained Géraldine Andrieux, CEO of Blumorpho. Featured case studies included Ineos Energy's integrated approach to carbon capture and storage, and Republic Bank's expanding role in green infrastructure across Caribbean ports and beyond. 'As key players in the globalisation of trade, port cities bear a large share of the responsibility for the climate change. But the richness of their ecosystem means that they are also home to some of the solutions,' said Bruno Delsalle, General Manager of AIVP. The session sets the stage for a shared roadmap to be presented at the AIVP World Conference Cities & Ports 2025, scheduled in New York this November. Tisha Marajh, Group Sustainability Officer at Republic Bank, concluded with a firm call to action: 'We don't have time to waste. We are among the most affected by climate change. Phased investments tailored to attract different kinds of financing can provide a more sustainable path forward. We also need systems to identify small upstream projects, manage ESG risks, and facilitate technology transfer. Sustainable finance is a market opportunity, and we, as financial institutions, are ready to engage, if the right conditions are in place, in Caribbeans and at global scale.' For more information:- A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
